Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

By sjmartinez • August 28, 2022

Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. PMID: 35739268.

Tags: Hematology/Oncology, Publications

Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence

Sugumar K, Alabd A, Alabd A, Hue JJ, Lyons J, Fields S, Wainberg Z, Zheng L, Coogle B, Kasi A, Grewal N, Kindler HL, Starr[...]

Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06

Shami R, Salgado R, Bardia A, Curigliano G, Hu X, Dent R, Pierga JY, Tsurutani J, Wildiers H, Ricciardi G, Marchiò C, Penault-Llorca F, Bor-Angelier[...]

Cutaneous manifestation of metastatic papillary thyroid carcinoma

Peng D, Dong E, Martinez D, Kang Y, Wong D, Holland V. Cutaneous manifestation of metastatic papillary thyroid carcinoma. JAAD Case Rep. 2025 Apr 11;60:129-131.[...]